Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INVANASDAQ:KNSANASDAQ:MRUSNASDAQ:PNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$18.61+0.3%$17.92$15.20▼$21.28$1.17B0.35634,692 shs546,033 shsKNSAKiniksa Pharmaceuticals$26.84+3.1%$22.51$17.38▼$28.56$1.95B0.07480,548 shs308,978 shsMRUSMerus$42.41+3.7%$43.51$33.19▼$61.61$2.94B0.94719,150 shs744,584 shsPNTPOINT Biopharma Global$12.98$6.57▼$14.35$1.33BN/A1.44 million shs3.29 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva0.00%-0.85%+5.94%+1.98%+18.97%KNSAKiniksa Pharmaceuticals0.00%-5.64%+35.11%+33.11%+33.59%MRUSMerus0.00%-6.49%-1.55%+1.67%-7.19%PNTPOINT Biopharma Global0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINVAInnoviva4.2404 of 5 stars3.50.00.04.22.82.51.9KNSAKiniksa Pharmaceuticals2.6522 of 5 stars3.51.00.00.03.23.30.6MRUSMerus3.2505 of 5 stars4.63.00.00.03.21.70.0PNTPOINT Biopharma GlobalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINVAInnoviva 3.00Buy$55.00195.54% UpsideKNSAKiniksa Pharmaceuticals 3.00Buy$38.8044.56% UpsideMRUSMerus 3.13Buy$85.15100.79% UpsidePNTPOINT Biopharma Global 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KNSA, INVA, PNT, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.004/29/2025KNSAKiniksa PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/16/2025KNSAKiniksa PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.004/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.003/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/18/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/13/2025KNSAKiniksa PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.003/10/2025MRUSMerusBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.003/7/2025INVAInnovivaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/3/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINVAInnoviva$369.84M3.15$3.60 per share5.17$10.66 per share1.75KNSAKiniksa Pharmaceuticals$481.17M4.05N/AN/A$6.23 per share4.31MRUSMerus$36.13M81.24N/AN/A$6.17 per share6.87PNTPOINT Biopharma Global$226.58M0.00N/A13.31$4.68 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINVAInnoviva$179.72M-$1.0126.9712.01N/A18.31%20.84%11.38%5/14/2025 (Estimated)KNSAKiniksa Pharmaceuticals$14.08M-$0.25N/A107.36N/A-2.36%-7.31%-5.95%7/22/2025 (Estimated)MRUSMerus-$154.94M-$4.08N/AN/AN/A-680.61%-38.89%-31.16%5/14/2025 (Estimated)PNTPOINT Biopharma Global$98.29M$0.9013.89N/AN/A39.62%21.10%18.28%N/ALatest KNSA, INVA, PNT, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals$0.02$0.11+$0.09$0.11$128.35 million$137.79 million2/27/2025Q4 2024MRUSMerus-$0.89-$0.41+$0.48-$0.41$10.57 million$9.14 million2/26/2025Q4 2024INVAInnovivaN/A$0.57N/A$0.26N/A$91.81 million2/25/2025Q4 2024KNSAKiniksa Pharmaceuticals-$0.06-$0.12-$0.06-$0.12$123.42 million$122.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINVAInnovivaN/AN/AN/AN/AN/AKNSAKiniksa PharmaceuticalsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/APNTPOINT Biopharma GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINVAInnoviva0.381.791.64KNSAKiniksa PharmaceuticalsN/A3.242.95MRUSMerusN/A8.328.32PNTPOINT Biopharma Global0.019.149.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINVAInnoviva99.12%KNSAKiniksa Pharmaceuticals53.95%MRUSMerus96.14%PNTPOINT Biopharma Global59.53%Insider OwnershipCompanyInsider OwnershipINVAInnoviva2.25%KNSAKiniksa Pharmaceuticals54.57%MRUSMerus4.57%PNTPOINT Biopharma Global16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINVAInnoviva10062.68 million61.54 millionOptionableKNSAKiniksa Pharmaceuticals22072.64 million32.80 millionOptionableMRUSMerus3769.21 million65.34 millionOptionablePNTPOINT Biopharma Global129106.57 million89.52 millionOptionableKNSA, INVA, PNT, and MRUS HeadlinesRecent News About These CompaniesLantheus on POINT in radio-oncology with $2bn licensing dealSeptember 14, 2024 | pharmaphorum.comSustainability: A Key Differentiator as Biopharma Faces Momentum Challenges, According to Global Survey by CytivaAugust 21, 2024 | genengnews.comProta Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick MachadoJuly 24, 2024 | markets.businessinsider.comHow to deliver an effective global strategic brand planJuly 19, 2024 | pharmaphorum.comWhat's Going On With GT Biopharma Stock?May 20, 2024 | msn.comHow Merck is stepping up for patientsMay 19, 2024 | pharmaphorum.comPoint Digital Finance prints second HEI RMBSMay 9, 2024 | globalcapital.comInvesting in biopharma innovation: Can you stay one step ahead?April 8, 2024 | bloomberg.comGlobal Point of Care Molecular Diagnostics Industry Aims for a Striking US$11.1 Billion Market by 2033, Fueled by a 9.7% CAGR | FMIMarch 14, 2024 | fmiblog.comReshaping The Global Neopentyl Glycol Dicaprate Market With Latest Trends And Market OpportunitiesFebruary 21, 2024 | opprairie.comComprehensive Overview of the Pharmaceutical Grade Ambrisentan Market along with Emerging Trends, Challenges, and Potential ThreatsFebruary 13, 2024 | opprairie.comDomain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology CompanyJanuary 8, 2024 | businesswire.comLilly Completes Acquisition of POINT BiopharmaDecember 27, 2023 | finance.yahoo.comPOINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition ProspectsDecember 22, 2023 | markets.businessinsider.comBrookline Capital Downgrades POINT Biopharma Global (PNT)December 22, 2023 | msn.comPOINT Biopharma Global Stock (NASDAQ:PNT), Guidance and ForecastDecember 22, 2023 | benzinga.comLilly extends tender offer for POINT Biopharma to Dec. 22December 18, 2023 | msn.comWhy POINT Biopharma Global Is At Least A Hold On Disappointing ReadoutDecember 18, 2023 | seekingalpha.comLantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study ResultsDecember 18, 2023 | markets.businessinsider.comPOINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should KnowDecember 8, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKNSA, INVA, PNT, and MRUS Company DescriptionsInnoviva NASDAQ:INVA$18.61 +0.05 (+0.27%) Closing price 04:00 PM EasternExtended Trading$18.59 -0.02 (-0.10%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Kiniksa Pharmaceuticals NASDAQ:KNSA$26.84 +0.81 (+3.11%) Closing price 04:00 PM EasternExtended Trading$27.19 +0.35 (+1.30%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Merus NASDAQ:MRUS$42.41 +1.51 (+3.69%) Closing price 04:00 PM EasternExtended Trading$42.54 +0.13 (+0.31%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.POINT Biopharma Global NASDAQ:PNTPOINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
